Scienture Receives Patent Approval for REZENOPY™ Nasal Spray, Strengthening IP Protection and Commercial Strategy

Scienture Holdings has announced the issuance of a US patent covering its REZENOPYTM naloxone HCl nasal spray, the highest dosage approved by the FDA for life-saving opioid overdose treatment. The patent, with an expiry date of February 5, 2041, adds intellectual property protection to the product's US commercialization. Scienture entered into a collaboration with Summit Biosciences in March 2025 for exclusive US commercialization rights. REZENOPYTM received FDA approval in April 2024 and the US naloxone market is valued at approximately $154 million annually.